Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The "Systemic Sclerosis (Scleroderma) - Global Clinical Trials Review, 2025" report has been added to ResearchAndMarkets.com's offering. The clinical trial ...
Localized scleroderma, as the term denotes, is localized to the skin on the hands and face. It is characterized by slow progression and rarely transforms to the systemic type. Localized scleroderma is ...
Report Ocean presents a new report on Systemic scleroderma treatment market size, share, growth, industry trends, and forecast 2030, covering various industry elements and growth trends helpful for ...
The global systemic scleroderma treatment market expected to reach USD 2.2 billion by 2028 according to a new study by Report Ocean. The report “Systemic Scleroderma Treatment Market Report, By Drug ...
Although less common than other subtypes of systemic sclerosis (SSc), systemic sclerosis sine scleroderma (ssSSc) makes up more than 8% of SSc cases and "should not be neglected," according to a new ...
Fibrosis, or the scaring of tissue, occurs in many diseases, and is a central component of systemic sclerosis. There are currently no treatments that can reverse fibrosis and the current treatment ...
Scleroderma on the face can cause symptoms that may affect your appearance, including the texture, discoloration, and elasticity of your skin. Medications, facial exercises, and dermatological ...
Systemic sclerosis sine scleroderma (ssSSc) affects nearly 10% of patients with systemic sclerosis (SSc), with substantial internal organ involvement. Despite lacking skin fibrosis, patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results